Kringle Pharma, Inc. (4884) Stock Statistics & Valuation Metrics

Kringle Pharma, Inc. has a market cap or net worth of ¥6.97B. The enterprise value is ¥4.55B.

Kringle Pharma, Inc. has 6,837,200 shares outstanding. The number of shares has decreased by -2.65% in one year.

Kringle Pharma, Inc.’s return on equity (ROE) is -0.36 and return on invested capital (ROIC) is -31.16%.

The current PE Ratio of Kringle Pharma, Inc. is -7.17. Kringle Pharma, Inc.’s PEG ratio is 0.58.

In the last 12 months, Kringle Pharma, Inc. had revenue of 80.04M and earned -756.45M in profits. Earnings per share was -118.21.

In the last 12 months, operating cash flow was 0.00 and capital expenditures 0.00, giving a free cash flow of 0.00 billion.

Kringle Pharma, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―

Kringle Pharma, Inc. upcoming earnings date is Aug 8, 2025, TBA Not Confirmed.

Kringle Pharma, Inc. as a current ratio of 21.50, with Debt / Equity ratio of 0.00%

In the past 12 months, Kringle Pharma, Inc. has paid 1.49M in taxes.

Kringle Pharma, Inc. EV to EBITDA ratio is -3.80, with an EV/FCF ratio of -4.70.

Kringle Pharma, Inc. has ¥2.10B in cash and marketable securities with ¥0.00 in debt, giving a net cash position of -¥2.10B billion.

Gross margin is 75.63%, with operating margin of -1021.87%, and net profit margin of -945.12%.

The average price target for Kringle Pharma, Inc. is ―, which is 11.43% higher than the current price. The consensus rating is ―